In constant efforts to improve the outcomes of patients with cancer, scientists frequently investigate old and commonly prescribed drugs for their potential antineoplastic features. For statins and metformin, two metabolic agents which are both often prescribed, these antitumour properties have been suggested in preclinical studies [1, 2]. Recent phase 3 trials of androgen receptor signalling inhibitors may provide the opportunity to investigate these putative effects in patients with prostate cancer.
